The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma

被引：0
|
作者：
Rose, April A. N. [1 ]
Armstrong, Susan M. [1 ]
Hogg, David [2 ]
Butler, Marcus [2 ]
Joshua, Anthony M. [3 ]
Ghazarian, Danny [4 ]
Kamel-Reid, Suzanne [4 ]
Al Habeeb, Ayman [4 ]
Chappell, Mary Anne [2 ]
Ross, Kendra [2 ]
Amir, Eitan [2 ]
Bedard, Phillippe L. [2 ]
Siu, Lillian [2 ]
Spreafico, Anna [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Kinghorn Canc Ctr, Sydney, NSW, Australia
[4] Univ Hlth Network, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3141
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Activity of anti-PD1 drugs in uveal melanoma patients.
    Piperno-Neumann, Sophie
    Servois, Vincent
    Mariani, Pascale
    Cassoux, Nathalie
    Barnhill, Raymond
    Rodrigues, Manuel Jorge
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.
    De Rosa, Francesco
    Ridolfi, Laura
    Tanda, Enrica Teresa
    Marra, Elena
    Pigozzo, Jacopo
    Marconcini, Riccardo
    Guida, Michele
    Gallizzi, Giulia
    Occelli, Marcella
    Pala, Laura
    Gambale, Elisabetta
    Bersanelli, Melissa
    Conca, Raffaele
    Cortellini, Alessio
    Morgese, Francesca
    Zoratto, Federica
    Stucci, Luigia Stefania
    Strippoli, Sabino
    Petracci, Elisabetta
    Guidoboni, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
    Amato, Carol M.
    Hintzsche, Jennifer D.
    Wells, Keith
    Applegate, Allison
    Gorden, Nicholas T.
    Vorwald, Victoria M.
    Tobin, Richard P.
    Nassar, Kelsey
    Shellman, Yiqun G.
    Kim, Jihye
    Medina, Theresa M.
    Rioth, Matthew
    Lewis, Karl D.
    McCarter, Martin D.
    Gonzalez, Rene
    Tan, Aik-Choon
    Robinson, William A.
    CANCERS, 2020, 12 (07) : 1 - 15
  • [44] Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy in NRAS-mutant melanoma
    Phadke, Manali S.
    Chen, Zhihua
    Mohamed, Eslam
    Davies, Michael
    Chen, Ann
    Rix, Uwe
    Rodriguez, Paulo
    Smalley, Keiran
    CANCER RESEARCH, 2020, 80 (16)
  • [45] Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma
    Malmontet, T.
    Dousset, L.
    Gerard, E.
    Ouhabrache, N.
    Pham-Ledard, A.
    Beylot-Barry, M.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (03): : 228 - 232
  • [46] Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
    Prado Vazquez, G.
    Gamez Pozo, A.
    Trilla Fuertes, L.
    Zapater Moros, A.
    Lopez Camacho, E.
    Lopez Vacas, R.
    Diaz Almiron, M.
    Zamora, P.
    Fresno Vara, J. A.
    Espinosa, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S2 - S2
  • [47] A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
    Bigelow, Emma
    Saria, Suchi
    Piening, Brian
    Curti, Brendan
    Dowdell, Alexa
    Weerasinghe, Roshanthi
    Bifulco, Carlo
    Urba, Walter
    Finkelstein, Noam
    Fertig, Elana J.
    Baras, Alex
    Zaidi, Neeha
    Jaffee, Elizabeth
    Yarchoan, Mark
    CANCER INFORMATICS, 2022, 21
  • [48] FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
    A. Flaus
    V. Habouzit
    N. De Leiris
    J. P. Vuillez
    M. T. Leccia
    J. L. Perrot
    N. Prevot
    F. Cachin
    Scientific Reports, 11
  • [49] Cyclooxygenase inhibition and response to anti-PD1/L1 in advanced melanoma.
    Johnpulle, Romany Anne Nilanthi
    Pollack, Megan Lynn Hames
    Riemenschneider, Kelsie
    Puzanov, Igor
    Sosman, Jeffrey Alan
    Johnson, Douglas Buckner
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Efficacy of ANTI-PD1 Immunotherapy for Skin Carcinomas and Malign Melanoma in a Child with Xeroderma Pigmentosum
    Cabi, E. Unal
    Tanyildiz, H. G.
    Tacyildiz, N.
    Dincaslan, H.
    Kaya, B.
    Tuncer, H. Erkol
    Cakmak, M.
    Heper, A. Okcu
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S620 - S620
12345